The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Butacote     4-butyl-1,2-diphenyl- pyrazolidine-3,5-dione

Synonyms: Anpuzone, Artrizin, Butadion, Butapirazol, Butazolidin, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of phenylbutazone


Psychiatry related information on phenylbutazone


High impact information on phenylbutazone


Chemical compound and disease context of phenylbutazone


Biological context of phenylbutazone

  • In fact, CGD PMN had an ADCC against BCNU-treated Raji cells lower than that mediated by normal PMN, but comparable to that observed with untreated targets, and phenylbutazone reduced the lysis of BCNU-treated Raji cells by normal PMN to the level observed with the use of untreated targets [3].
  • Phenylbutazone interfered with binding of N-formyl-methionyl-leucyl-[3H]phenylalanine but not [125I]C5a to the neutrophil, displaced labeled tripeptide bound in the absence of PBZ, increased the dissociation constant (KD) for labeled tripeptide, and limited down regulation of peptide receptor function [11].
  • Highly protein-bound drugs (such as phenylbutazone, phenytoin, or warfarin) can compete with the common binding sites of salicylates [18].
  • The effect of malnutrition on the pharmacokinetics of phenylbutazone [19].
  • Dietary protein deprivation led to a decrease in the plasma clearance and plasma protein binding of phenylbutazone but did not lead to a change in its bioavailability [20].

Anatomical context of phenylbutazone


Associations of phenylbutazone with other chemical compounds


Gene context of phenylbutazone


Analytical, diagnostic and therapeutic context of phenylbutazone


  1. Aplastic anemia from veterinary phenylbutazone. Ramsey, R., Golde, D.W. JAMA (1976) [Pubmed]
  2. Agranulocytosis caused by Chinese herbal medicines. Dangers of medications containing aminopyrine and phenylbutazone. Ries, C.A., Sahud, M.A. JAMA (1975) [Pubmed]
  3. Antibody-dependent killing of tumor cells by polymorphonuclear leukocytes. Involvement of oxidative and nonoxidative mechanisms. Dallegri, F., Patrone, F., Frumento, G., Sacchetti, C. J. Natl. Cancer Inst. (1984) [Pubmed]
  4. Phenylbutazone liver injury: a clinical-pathologic survey of 23 cases and review of the literature. Benjamin, S.B., Ishak, K.G., Zimmerman, H.J., Grushka, A. Hepatology (1981) [Pubmed]
  5. Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis. Weiner, G.I., White, S.R., Weitzner, R.I., Rubinstein, H.M. Arthritis Rheum. (1979) [Pubmed]
  6. Differential effects of phenylbutazone and local anesthetics on nociception in the equine. Kamerling, S.G., Dequick, D.J., Weckman, T.J., Sprinkle, F.P., Tobin, T. Eur. J. Pharmacol. (1984) [Pubmed]
  7. Renal papillary necrosis in horses after phenylbutazone and water deprivation. Gunson, D.E., Soma, L.R. Vet. Pathol. (1983) [Pubmed]
  8. Biochemical and haematological effects of phenylbutazone in horses. Lees, P., Creed, R.F., Gerring, E.E., Gould, P.W., Humphreys, D.J., Maitho, T.E., Michell, A.R., Taylor, J.B. Equine Vet. J. (1983) [Pubmed]
  9. Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine. Roberge, C.J., Gaudry, M., de Médicis, R., Lussier, A., Poubelle, P.E., Naccache, P.H. J. Clin. Invest. (1993) [Pubmed]
  10. Long-term studies on carcinogenicity and promoting effect of phenylbutazone in DONRYU rats. Meakawa, A., Onodera, H., Tanigawa, H., Furuta, K., Kanno, J., Matsuoka, C., Ogiu, T., Hayashi, Y. J. Natl. Cancer Inst. (1987) [Pubmed]
  11. Chemotactic deactivation of human neutrophils: protective influence of phenylbutazone. Nelson, R.D., Gracyk, J.M., Fiegel, V.D., Herron, M.J., Chenoweth, D.E. Blood (1981) [Pubmed]
  12. Genetic control of interindividual variations in the inducibility of aryl hydrocarbon hydroxylase in cultured human lymphocytes. Atlas, S.A., Vesell, E.S., Nebert, D.W. Cancer Res. (1976) [Pubmed]
  13. Mechanism of action of colchicine. III. Antiinflammatory effects of colchicine compared with phenylbutazone and indomethacin. Chang, Y.H. Arthritis Rheum. (1975) [Pubmed]
  14. Mianserin and agranulocytosis in New Zealand. Coulter, D.M., Edwards, I.R. Lancet (1990) [Pubmed]
  15. Aroyl- and arylisoquinolineacetic acids as antiinflammatory agents. Walsh, D.A., Sancilio, L.F., Reese, D.L. J. Med. Chem. (1978) [Pubmed]
  16. Sulphasalazine and PhCL28A inhibit the formation of ethanol- and phenylbutazone-induced rat gastric ulcers: lack of involvement of endogenous prostaglandins? Berry, C.N., Prouteau, M., Lloyd, K.G. Br. J. Pharmacol. (1988) [Pubmed]
  17. Generalized pustular psoriasis precipitated by phenylbutazone and oxyphenbutazone. Reshad, H., Hargreaves, G.K., Vickers, C.F. Br. J. Dermatol. (1983) [Pubmed]
  18. Interactions of analgesics with other drugs. Klotz, U. Am. J. Med. (1983) [Pubmed]
  19. The effect of malnutrition on the pharmacokinetics of phenylbutazone. Krishnaswamy, K., Ushasri, V., Naidu, N.A. Clinical pharmacokinetics. (1981) [Pubmed]
  20. Influence of dietary protein on the anti-inflammatory and ulcerogenic effects and on the pharmacokinetics of phenylbutazone in rats. Varma, D.R. J. Pharmacol. Exp. Ther. (1979) [Pubmed]
  21. The effect of anti-inflammatory agents and inflammation on granulocyte adherence. Evidence for regulation by plasma factors. MacGregor, R.R. Am. J. Med. (1976) [Pubmed]
  22. Prostaglandin hydroperoxidase-dependent oxidation of phenylbutazone: relationship to inhibition of prostaglandin cyclooxygenase. Hughes, M.F., Mason, R.P., Eling, T.E. Mol. Pharmacol. (1988) [Pubmed]
  23. Enhanced susceptibility of Escherichia coli to intracellular killing by human polymorphonuclear leukocytes after in vitro incubation with chloramphenicol. Pruul, H., Wetherall, B.L., McDonald, P.J. Antimicrob. Agents Chemother. (1981) [Pubmed]
  24. Cytotoxicity of human peripheral blood and colostral leukocytes against Shigella species. Morgan, D.R., DuPont, H.L., Gonik, B., Kohl, S. Infect. Immun. (1984) [Pubmed]
  25. Involvement of leukocytes in the oxygenation and chlorination reaction of phenylbutazone. Ichihara, S., Tomisawa, H., Fukazawa, H., Tateishi, M., Joly, R., Heintz, R. Biochem. Pharmacol. (1986) [Pubmed]
  26. Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with phenylbutazone. Lomen, P.L., Turner, L.F., Lamborn, K.R., Brinn, E.L., Sattler, L.P. Am. J. Med. (1986) [Pubmed]
  27. Effect of oral contraceptives on plasma clearance. Carter, D.E., Bressler, R., Hughes, M.R., Haussler, M.R., Christian, D., Heine, M.W. Clin. Pharmacol. Ther. (1975) [Pubmed]
  28. Increased adhesiveness of complement-stimulated neonatal calf neutrophils and its pharmacologic inhibition. Zwahlen, R.D., Slauson, D.O., Neilsen, N.R., Clifford, C.B. J. Leukoc. Biol. (1987) [Pubmed]
  29. Multicentre trial of naproxen and phenylbutazone in acute gout. Sturge, R.A., Scott, J.T., Hamilton, E.B., Liyanage, S.P., Dixon, A.S., Davies, J., Engler, C. Ann. Rheum. Dis. (1977) [Pubmed]
  30. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. Laneuville, O., Breuer, D.K., Dewitt, D.L., Hla, T., Funk, C.D., Smith, W.L. J. Pharmacol. Exp. Ther. (1994) [Pubmed]
  31. Evaluation of the ability of carprofen and flunixin meglumine to inhibit activation of nuclear factor kappa B. Bryant, C.E., Farnfield, B.A., Janicke, H.J. Am. J. Vet. Res. (2003) [Pubmed]
  32. European experience with flurbiprofen. A new analgesic/anti-inflammatory agent. Buchanan, W.W., Kassam, Y.B. Am. J. Med. (1986) [Pubmed]
  33. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. Takeda, M., Khamdang, S., Narikawa, S., Kimura, H., Hosoyamada, M., Cha, S.H., Sekine, T., Endou, H. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  34. Promotion of oxidative damage to arachidonic acid and alpha 1-antiproteinase by anti-inflammatory drugs in the presence of the haem proteins myoglobin and cytochrome C. Evans, P.J., Akanmu, D., Halliwell, B. Biochem. Pharmacol. (1994) [Pubmed]
  35. Hemoperfusion for phenylbutazone poisoning. Berlinger, W.G., Spector, R., Flanigan, M.J., Johnson, G.F., Groh, M.R. Ann. Intern. Med. (1982) [Pubmed]
  36. Phenylbutazone-induced systemic vasculitis with crescentic glomerulonephritis. Leung, A.C., McLay, A., Dobbie, J.W., Jones, J.M. Arch. Intern. Med. (1985) [Pubmed]
  37. Clinical pharmacokinetics of phenylbutazone. Aarbakke, J. Clinical pharmacokinetics. (1978) [Pubmed]
  38. Effects of various prostaglandin synthesis inhibitors on pancreatic carcinogenesis in hamsters after initiation with N-nitrosobis(2-oxopropyl)amine. Takahashi, M., Furukawa, F., Toyoda, K., Sato, H., Hasegawa, R., Imaida, K., Hayashi, Y. Carcinogenesis (1990) [Pubmed]
  39. Double-blind trial of naproxen and phenylbutazone in ankylosing spondylitis. Van Gerwen, F., Van der Korst, J.K., Gribnau, F.W. Ann. Rheum. Dis. (1978) [Pubmed]
WikiGenes - Universities